Overview
I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine. I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies. I am also the Chair of the SWOG Leukemia Committee. I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia. Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.
Office Hours
Office hours:
Monday, 8 a.m. to 12 p.m.
Tuesday, 8 a.m. to 5 p.m.
Wednesday, 8 a.m. to 12 p.m.
Friday, 1 p.m. to 5 p.m.
Current Duke Appointments & Affiliations
Professor of Medicine
·
2023 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.
Journal article Blood Neoplasia · November 2026 Nucleophosmin-1 (NPM1) mutations define a major molecular subtype of acute myeloid leukemia (AML) and is generally associated with favorable prognosis. However, the impact of myelodysplastic syndrome-associated mutations (MDSm+) on patient outcomes within ... Full text Link to item CiteGenomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.
Journal article Blood · October 5, 2026 The bispecific CD19/CD3 T-cell engaging antibody blinatumomab is efficacious in front-line therapy in B-cell acute lymphoblastic leukemia (B-ALL) but the biological determinants of response and resistance are incompletely understood. To examine the genomic ... Full text Link to item CiteZiftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.
Journal article Blood · October 1, 2026 Ziftomenib, a potent, selective, oral menin inhibitor, is approved as monotherapy for adults with relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (NPM1-m AML). The KOMET-007 phase 1 trial investigated clinical activity and tolerability of zif ... Full text Link to item CiteRecent Grants
The Duke University - Duke Cancer Institute National Clinical Trials Network Lead Academic Participating Site (UG1) Support Grant
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2032A Multi-Center, Randomized, Controlled Cross-Over Study to Evaluate the Safety and Effectiveness of Hypoxic Red Blood Cells Processed with the Hemanext ONE® System versusConventional Red Blood Cells in Patients with Transfusion-Dependent Haematologi
Clinical TrialPrincipal Investigator · Awarded by Hemanext Inc. · 2026 - 2031Study of AZD3632 Monotherapy or in Combination with Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or other Genotypes Associated with HOX Overexpression.
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2030View All Grants
Education
Stanford University, School of Medicine ·
1988
M.D.
Stanford University ·
1988
Ph.D.